Search
TEL540-548
go.drugbank.com/drugs/DB17461InvestigationalTEL540-548 is a recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT).
Denifanstat
go.drugbank.com/drugs/DB17576InvestigationalDue to its antineoplastic activities, it is being investigated for various cancers.
Narazaciclib
go.drugbank.com/drugs/DB19038InvestigationalNarazaciclib is under investigation in clinical trial NCT06351644 (On 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed And/or Refractory Multiple Myeloma).
Mexazolam
go.drugbank.com/drugs/DB15489Investigational[A184910] Mexazolam's structure is similar to that of other benzodiazepines such as [oxazolam] and [cloxazolam].
3-(5-Amino-3-imino-3H-pyrazol-4-ylazo)-benzoic acid
go.drugbank.com/drugs/DB08668ExperimentalThis compound belongs to the aminobenzoic acid derivatives. … These are benzoic acids (or derivatives thereof) containing an amine group attached to the benzene moiety. 3-(5-amino-3-imino-3H-pyrazol-4-ylazo)-benzoic acid targets the protein methionine aminopeptidase
Fenbendazole
go.drugbank.com/drugs/DB11410InvestigationalVet approvedFenbendazole is approved to be administered under veterinary to sheep, cattle, horses, fish, dogs, cats, rabbits and seals.
VB10.16
go.drugbank.com/drugs/DB17512InvestigationalVB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. … It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting
Cepharanthine
go.drugbank.com/drugs/DB16824InvestigationalCategories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalDalotuzumab
go.drugbank.com/drugs/DB11840InvestigationalDalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
Pexastimogene devacirepvec
go.drugbank.com/drugs/DB15069InvestigationalPexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma).